<DOC>
	<DOCNO>NCT01975610</DOCNO>
	<brief_summary>CC-292 oral agent clinical development treatment rheumatoid arthritis autoimmune inflammatory disorder . This study test clinical effectiveness safety orally ( PO ) administer dose CC-292 compare placebo US female patient currently background Methotrexate ( MTX ) active Rheumatoid Arthritis ( RA</brief_summary>
	<brief_title>Efficacy Safety Study CC-292 Versus Placebo Co-therapy With Methotrexate Active Rheumatoid Arthritis</brief_title>
	<detailed_description>This Phase 2a , multicenter , randomize , double-blind , placebo-controlled , proof-of-concept study determine efficacy safety CC-292 ( 375 mg PO daily ) stable background MTX therapy female subject active RA . Approximately 80 female subject active RA randomize 1:1 two dose group : active CC-292 ( 375 mg PO daily ) identically-appearing placebo capsule 4 week</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>Female 18 80 year age ( inclusive ) time sign informed consent . Must meet 2010 ACR/EULAR Classification Criteria RA ( Appendix A ) , RA least 6 month must continue active RA time randomization despite least 3 month treatment stable dos MTX ( 7.5 25 mg/week oral parenteral ) least 4 week prior randomization . Must treat MTX least 3 month prior randomization , must stable dose 7.5 25 mg/week ( PO parenteral , ) least 4 week prior randomization . Subjects require maintain stable dose Day 28/Week 4 study . Oral folate supplementation require minimum dose 5 mg/week ( ie , folic acid ) subject take MTX . Leucovorin may use instead folic acid may dose 10 mg/week orally . Sulfasalazine allow concomitant medication , however , subject must stable dose least 4 week prior randomization Day 28/Week 4 study . Hydroxychloroquine chloroquine allow concomitant medication , however , subject must stable dose least 4 week prior randomization Day 28/Week 4 study . Modification Diet Renal Disease formula ( MDRD ) estimate glomerular filtration rate ( MDRD eGFR ) ≥ 60 mL/min/1.73m2+ Male subject Any condition could affect CC292 absorption , include gastric restriction , bariatric surgery , gastric bypass , clinical condition associate decreased intragastric acid production acid pernicious anemia . Currently use treatment DMARDs ( sulfasalazine , hydroxychloroquine chloroquine MTX ) , include biologics . Previous use allow adequate washout ( 4 week 5 halflives , whichever long ) prior randomization . Previous treatment cell deplete therapy , include investigational agent ( eg , CAMPATH , antiCD4 , antiCD5 , antiCD3 , antiCD19 antiCD20 ) within 6 month screen . Treatment intravenous gamma globulin , plasmapheresis Prosorba® column within 2 week prior randomization . Intraarticular parenteral corticosteroid allow within 2 week prior randomization .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Arthritis , Rheumatoid , Autoimmune , Inflammatory , Synovial , Bruton 's tyrosine kinase ( Btk ) , CC-292 , Joint Disease</keyword>
</DOC>